Calcium + Vitamin D3 + Multimineral interactions
Checked as Cholecalciferol in this data source.
Full monograph for Calcium + Vitamin D3 + MultimineralCheck it against another medicine
Medicines
47 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Aluminium Hydroxide + Magnesium Hydroxide | Major | Absorption · Synergy | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms | 6 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Major | Absorption · Synergy | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms | 6 sources — open the full entry |
| Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Citrate + Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Doxercalciferol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Paricalcitol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Sucralfate | Major | Absorption | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in… | 2 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Calcium acetate + Magnesium carbonate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Digoxin | Moderate | Synergy | Excessive dosing of vitamin D can induce hypercalcemia, which may increase the risk of digitalis toxicity and serious arrhythmias due to additive inotropic… | 6 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Indapamide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Indapamide + Amlodipine | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Irbesartan + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Iron Sucrose | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Losartan Potassium + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Magnesium Hydroxide | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Magnesium Hydroxide + Liquid Paraffin | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Magnesium Oxide | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Magnesium Sulfate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Metolazone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Nebivolol + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Olmesartan Medoxomil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Oxcarbazepine | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Perindopril + Indapamide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Phenobarbital | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Phenytoin Sodium | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Primidone | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Ramipril + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Rifampicin | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Rifampicin + Isoniazid | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin…2 documented mechanisms | 4 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin…2 documented mechanisms | 4 sources — open the full entry |
| Sevelamer Carbonate | Moderate | Absorption | INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. In non-clinical… | 7 sources — open the full entry |
| Sevelamer Hydrochloride | Moderate | Absorption | INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. In non-clinical… | 7 sources — open the full entry |
| Sodium Picosulfate + Magnesium Oxide + Citric Acid | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Telmisartan + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Triamterene + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Valsartan + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Orlistat | Minor | Absorption | Orlistat decreases the absorption of fat-soluble vitamins. Vitamin supplements should be taken at least two hours before or after orlistat administration. | 1 sources — open the full entry |
Conditions
Conditions in which Calcium + Vitamin D3 + Multimineral needs care, as documented in this source.
Arrhythmias, Cardiac
MajorVitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Hypercalcemia
MajorVitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
4 sources
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
- "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc (2002):
- "Product Information. Drisdol (ergocalciferol)." sanofi-aventis (2016):
Kidney Diseases
MajorErgocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Water-Electrolyte Imbalance
MajorVitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
4 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
Liver Diseases
ModerateVitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Therapeutic duplication
Drug classes that overlap with Calcium + Vitamin D3 + Multimineral, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Os-cal extra d3